Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets.
[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text] October 26, 2018 VANCOUVER, British Columbia — Vancouver based microbiome startup Derm-Biome Pharmaceuticals Inc. is excited to announce that it has contracted the Centre for Drug Research and Development (CDRD) to commence testing its patented compounds on various pathogens. Lead compound DB-207 shows significant potential in patients […]